The information in this section is intended for visitors outside the United States.
Since the founding of Gilead in 1987, we have focused on developing and delivering medications that advance the treatment of life-threatening diseases. The commercial success of our products provides us with the resources to generate new clinical data defining their profiles and supports our development of new therapeutic advancements. As we bring new products into clinical development, our goal remains the same–to discover, develop and commercialize therapeutics that advance patient care.
Our research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, oncology and inflammation, and cardiovascular and respiratory conditions.
Our research and development effort is the largest it has ever been; with more than 250 ongoing and planned clinical studies evaluating compounds with potential to become next-generation therapies.
2013 Annual Review